Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).

Dirk Schadendorf, Antoni Ribas, Axel Hauschild et al.|Journal of Clinical Oncology|2015

Cited by 2